Chugai launches Tecentriq Intravenous Infusion 840 mg for treating TNBC
Category: #healthcare  By Mateen Dalal  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Chugai launches Tecentriq Intravenous Infusion 840 mg for treating TNBC
  • This would be the first registered immune checkpoint inhibitor for treating PD-L1-positive TNBC in Japan.
     
  • The drug has also been listed on NHI reimbursement price list.

Chugai Pharmaceutical Co. Ltd., a Japanese drug manufacturer, has reportedly announced the launch of  Tecentriq® (atezolizumab) Intravenous Infusion 840 mg for treatment of PD-L1 positive TNBC. The drug has been listed on (NHI) reimbursement price list. Tecentriq 840 mg is an ideal formulation for treating PD-L1-positive and HER2-negative recurrent or breast cancer.

Dr. Osamu Okuda, Executive Vice President and Co-Head of Project & Lifecycle Management Unit, Chugai, said that in recent years, immune checkpoint inhibitor has changed the treatment landscape for several types of cancers. The company is pleased to offer Tecentriq as the first approved drug in the breast cancer field to patients suffering from PD-L1 positive TNBC.

Okuda added that TNBC is rapidly progressing and aggressive disease with restricted treatment options and huge unmet medical needs. The company would be engaged in providing information, aiming to benefit patients by offering this new cancer immunotherapy-based treatment for TNBC. 

Basically, Tecentriq is an immune checkpoint inhibitor that targets PD-L1; a protein expressed on tumor-infiltrating immune cells and tumor cells. PD-L1 stops T-cell activity by binding with B7.1 and PD-1 receptors on the T-cell surface.

By reducing PD-L1, Tecentriq could activate T-cells and improve immune response against cancer cells. The safety and efficacy of Tecentriq were examined in phase III IMpassion130 clinical trial. 

Reports state that, in Japan, around 86,500 women suffer from breast cancer each year. Out of this, 14,800 women die as a result of this disease. As one of the leading companies in the Japan’s oncology field, Chugai is dedicated to contributing to medical professionals and patients by presenting Tecentriq as a new treatment option and to improve access to medications.

Source Credit - https://www.chugai-pharm.co.jp/english/news/detail/20191127100000_671.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Advaxis reveals positive data from Phase 1/2 ADXS-503 trial for NSCLC
Advaxis reveals positive data from Phase 1/2 ADXS-503 trial for NSCLC
By Mateen Dalal

Advaxis, Inc., a clinical-stage biotechnology company developing and commercializing immunotherapy p...

Mustang Bio observes complete response for MB-106 in lymphoma patient
Mustang Bio observes complete response for MB-106 in lymphoma patient
By Mateen Dalal

  MB-106 has been developed for cancer in partnership with Fred Hutchinson Cancer Research C...

FDA approves three drugs for counter use through Rx-to-OTC process
FDA approves three drugs for counter use through Rx-to-OTC process
By Mateen Dalal

The U.S. FDA (Food and Drug Administration) has reportedly approved three drugs as an over-the-count...